异柠檬酸脱氢酶
肝内胆管癌
癌症研究
转录组
生物
肿瘤微环境
外显子组测序
IDH1
医学
病理
突变体
突变
分子生物学
基因
肿瘤细胞
遗传学
基因表达
生物化学
酶
作者
Xiang Xiao,Ziyang Liu,Chong Zhang,Li Zhao,Jie Gao,Changkun Zhang,Qi Cao,Jinghui Cheng,Hengkang Liu,Dingbao Chen,Qian Cheng,Ning Zhang,Ruidong Xue,Fan Bai,Jiye Zhu
出处
期刊:Advanced Science
[Wiley]
日期:2021-07-11
卷期号:8 (17): e2101230-e2101230
被引量:64
标识
DOI:10.1002/advs.202101230
摘要
Intrahepatic cholangiocarcinoma (ICC) is highly heterogeneous. Here, the authors perform exome sequencing and bulk RNA sequencing on 73 tumor regions from 14 ICC patients to portray the multi-faceted intratumor heterogeneity (ITH) landscape of ICC. The authors show that ITH is highly concordant across genomic, transcriptomic, and immune levels. Comparison of these data to 8 published datasets reveals significantly higher degrees of ITH in ICC than hepatocellular carcinoma. Remarkably, the authors find that high-ITH tumors highly overlap with the IDH (isocitrate dehydrogenase)-mutant subgroup (IDH-SG), comprising of IDH-mutated tumors and IDH-like tumors, that is, those IDH-wildtype tumors that exhibit similar molecular profiles to the IDH-mutated ones. Furthermore, IDH-SG exhibits less T cell infiltration and lower T cell cytotoxicity, indicating a colder tumor microenvironment (TME). The higher ITH and colder TME of IDH-SG are successfully validated by single-cell RNA sequencing on 17 503 cells from 4 patients. Collectively, the study shows that IDH mutant subgroup status, rather than IDH mutation alone, is associated with ITH and the TME of ICC tumors. The results highlight that IDH-like patients may also benefit from IDH targeted therapies and provide important implications for the diagnosis and treatment of ICC.
科研通智能强力驱动
Strongly Powered by AbleSci AI